In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma

Reference

• Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., Jones, D. T. W., Joyce, J. A., Kearns, P., Kieran, M. W., Mellinghoff, I. K., Merchant, M., Pfister, S. M., Pollard, S. M., Ramaswamy, V., … Gilbertson, R. J. (2019). Challenges to curing primary brain tumours. Nature Reviews. Clinical Oncology, 16(8), 509–520. https://doi.org/10.1038/s41571-019-0177-5
   PubMed Web of Science ®Google Scholar
• Allegra, M., Tutone, M., Tesoriere, L., Attanzio, A., Culletta, G., & Almerico, A. M. (2021). Evaluation of the IKKβ binding of indicaxanthin by induced-fit docking, binding pose metadynamics, and molecular dynamics. Frontiers in Pharmacology, 12, 701568. https://doi.org/10.3389/fphar.2021.701568
   PubMed Web of Science ®Google Scholar
• Andronesi, O. C., Rapalino, O., Gerstner, E., Chi, A., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013). Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. The Journal of Clinical Investigation, 123(9), 3659–3663. https://doi.org/10.1172/JCI67229
   PubMed Web of Science ®Google Scholar
• Bascur, J. P., Alegría-Arcos, M., Araya-Durán, I., Juritz, E. I., González-Nilo, F. D., Almonacid Corresp, D. E., Author, C., & Almonacid, D. E. (2018). IDH1 and IDH2 mutants identified in cancer lose inhibition by isocitrate because of a change in their binding sites. BioRxiv, 1–37. https://doi.org/10.1101/425025
   Google Scholar
• Berg, T. J., & Pietras, A. (2022). Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells. Seminars in Cancer Biology, 86, 846–856. https://doi.org/10.1016/j.semcancer.2022.02.011
   PubMed Web of Science ®Google Scholar
• Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., Kwak, E. L., Clark, J. W., Ryan, D. P., Deshpande, V., Dias-Santagata, D., Ellisen, L. W., Zhu, A. X., & Iafrate, A. J. (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist, 17(1), 72–79. https://doi.org/10.1634/theoncologist.2011-0386
   PubMed Web of Science ®Google Scholar
• Bowers, K. J., Chow, E., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., Klepeis, J. L., Kolossvary, I., Moraes, M. A., Sacerdoti, F. D., Salmon, J. K., Shan, Y., & Shaw, D. E. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters. IEEE, 43–43. https://doi.org/10.1109/SC.2006.54
   Google Scholar
• Cairns, R. A., Iqbal, J., Lemonnier, F., Kucuk, C., de Leval, L., Jais, J.-P., Parrens, M., Martin, A., Xerri, L., Brousset, P., Chong Chan, L., Chan, W.-C., Gaulard, P., & Mak, T. W. (2012). IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood, 119(8), 1901–1903. https://doi.org/10.1182/blood-2011
   PubMed Web of Science ®Google Scholar
• Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., Marks, K. M., Prins, R. M., Ward, P. S., Yen, K. E., Liau, L. M., Rabinowitz, J. D., Cantley, L. C., Thompson, C. B., Vander Heiden, M. G., & Su, S. M. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462(7274), 739–744. https://doi.org/10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• Domingo-Musibay, E., & Galanis, E. (2015). What next for newly diagnosed glioblastoma? Future Oncology (London, England), 11(24), 3273–3283. https://doi.org/10.2217/fon.15.258
   PubMed Web of Science ®Google Scholar
• Dubois, L. G., Campanati, L., Righy, C., D'Andrea-Meira, I., Spohr, T. C. L. d S. E., Porto-Carreiro, I., Pereira, C. M., Balça-Silva, J., Kahn, S. A., DosSantos, M. F., Oliveira, M. d A. R., Ximenes-da-Silva, A., Lopes, M. C., Faveret, E., Gasparetto, E. L., & Moura-Neto, V. (2014). Gliomas and the vascular fragility of the blood brain barrier. Frontiers in Cellular Neuroscience, 8, 418. https://doi.org/10.3389/fncel.2014.00418
   PubMed Web of Science ®Google Scholar
• Elkhaled, A., Jalbert, L. E., Phillips, J. J., Yoshihara, H. A. I., Parvataneni, R., Srinivasan, R., Bourne, G., Berger, M. S., Chang, S. M., Cha, S., & Nelson, S. J. (2012). Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Science Translational Medicine, 4(116), 1–19. https://doi.org/10.1126/scitranslmed.3002796
   Web of Science ®Google Scholar
• Ellis, H. P., Greenslade, M., Powell, B., Spiteri, I., Sottoriva, A., & Kurian, K. M. (2015). Current challenges in glioblastoma: Intratumour heterogeneity, residual disease, and models to predict disease recurrence. Frontiers in Oncology, 5, 251. https://doi.org/10.3389/fonc.2015.00251
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. https://doi.org/10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Home - Enamine. (n.d). Retrieved May 4, 2023, from https://enamine.net/
   Google Scholar
• Hu, C., Zeng, Z., Ma, D., Yin, Z., Zhao, S., Chen, T., Tang, L., & Zuo, S. (2022). Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening. Frontiers in Pharmacology, 13, 982375. https://doi.org/10.3389/fphar.2022.982375
   PubMed Web of Science ®Google Scholar
• Ikram, N., Mirza, M. U., Vanmeert, M., Froeyen, M., Salo-Ahen, O. M. H., Tahir, M., Qazi, A., & Ahmad, S. (2019). Inhibition of oncogenic kinases: An in vitro validated computational approach identified potential multi-target anticancer compounds. Biomolecules, 9(4), 124. https://doi.org/10.3390/biom9040124
   PubMed Web of Science ®Google Scholar
• Jawarkar, R. D., Sharma, P., Jain, N., Gandhi, A., Mukerjee, N., Al-Mutairi, A. A., Zaki, M. E. A., Al-Hussain, S. A., Samad, A., Masand, V. H., Ghosh, A., & Bakal, R. L. (2022). QSAR, molecular docking, MD simulation and MMGBSA calculations approaches to recognize concealed pharmacophoric features requisite for the optimization of ALK tyrosine kinase inhibitors as anticancer leads. Molecules, 27(15), 4951. https://doi.org/10.3390/molecules27154951
   PubMed Web of Science ®Google Scholar
• Jovčevska, I. (2019). Genetic secrets of long-term glioblastoma survivors. Bosnian Journal of Basic Medical Sciences, 19(2), 116–124. https://doi.org/10.17305/bjbms.2018.3717
   PubMed Web of Science ®Google Scholar
• Kan, L. K., Drummond, K., Hunn, M., Williams, D., O'Brien, T. J., & Monif, M. (2020). Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis. BMJ Neurology Open, 2(2), e000069. https://doi.org/10.1136/bmjno-2020-000069
   PubMedGoogle Scholar
• Konteatis, Z., Artin, E., Nicolay, B., Straley, K., Padyana, A. K., Jin, L., Chen, Y., Narayaraswamy, R., Tong, S., Wang, F., Zhou, D., Cui, D., Cai, Z., Luo, Z., Fang, C., Tang, H., Lv, X., Nagaraja, R., Yang, H., … Biller, S. A. (2020). Vorasidenib (AG-881): A first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Medicinal Chemistry Letters, 11(2), 101–107. https://doi.org/10.1021/acsmedchemlett.9b00509
   PubMed Web of Science ®Google Scholar
• Korshunova, M., Huang, N., Capuzzi, S., Radchenko, D. S., Savych, O., Moroz, Y. S., Wells, C. I., Willson, T. M., Tropsha, A., & Isayev, O. (2022). Generative and reinforcement learning approaches for the automated de novo design of bioactive compounds. Communications Chemistry, 5(1), 1–11. https://doi.org/10.1038/s42004-022-00733-0
   PubMed Web of Science ®Google Scholar
• Kouassi, K. A. R., Ganiyou, A., Didier, D. G. G., Benié, A., & Nahossé, Z. (2022). In silico docking of rhodanine derivatives and 3D-QSAR study to identify potent prostate cancer inhibitors. Computational Chemistry, 10(02), 19–52. https://doi.org/10.4236/cc.2022.102002
   Google Scholar
• Kravets, I. O., Dudenko, D. V., Pashenko, A. E., Borisova, T. A., Tolstanova, G. M., Ryabukhin, S. V., & Volochnyuk, D. M. (2021). Virtual screening in search for a chemical probe for angiotensin-converting enzyme 2 (Ace2). Molecules, 26(24), 7584. https://doi.org/10.3390/molecules26247584
   PubMed Web of Science ®Google Scholar
• Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. https://doi.org/10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Malarz, K., Mularski, J., Pacholczyk, M., & Musiol, R. (2020). The landscape of the anti-kinase activity of the IDH1 inhibitors. Cancers, 12(3), 536. https://doi.org/10.3390/cancers12030536
   PubMed Web of Science ®Google Scholar
• Murali, P., & Karuppasamy, R. (2022). Identification of novel mutant (R132H) isocitrate dehydrogenase 1 inhibitors for glioma therapy. Research Square, 1–17. https://doi.org/10.21203/rs.3.rs-1344831/v1
   Google Scholar
• Murugan, A. K., & Alzahrani, A. S. (2022). Isocitrate dehydrogenase IDH1 and IDH2 mutations in human cancer: Prognostic implications for gliomas. British Journal of Biomedical Science, 79, 10208. https://doi.org/10.3389/bjbs.2021.10208
   PubMed Web of Science ®Google Scholar
• Oliva, C. R., Markert, T., Ross, L. J., White, E. L., Rasmussen, L., Zhang, W., Everts, M., Moellering, D. R., Bailey, S. M., Suto, M. J., & Griguer, C. E. (2016). Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cells. The Journal of Biological Chemistry, 291(46), 24188–24199. https://doi.org/10.1074/jbc.M116.749978
   PubMed Web of Science ®Google Scholar
• Oliver, L., Lalier, L., Salaud, C., Heymann, D., Cartron, P. F., & Vallette, F. M. (2020). Drug resistance in glioblastoma: Are persisters the key to therapy ? Cancer Drug Resistance (Alhambra, Calif.), 3(3), 287–301. https://doi.org/10.20517/cdr.2020.29
   PubMedGoogle Scholar
• Oltvai, Z. N., Harley, S. E., Koes, D., Michel, S., Warlick, E. D., Nelson, A. C., Yohe, S., & Mroz, P. (2021). Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. Molecular Case Studies, 7(2), a006007. https://doi.org/10.1101/mcs.a006007
   Google Scholar
• Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-oncology, 21(Suppl 5), V1–V100. Oxford University Press. https://doi.org/10.1093/neuonc/noz150
   PubMed Web of Science ®Google Scholar
• Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro-oncology, 24(Suppl 5), v1–v95. https://doi.org/10.1093/neuonc/noac202
   PubMedGoogle Scholar
• Pandi, S., Kulanthaivel, L., Subbaraj, G. K., Rajaram, S., & Subramanian, S. (2022). Screening of potential breast cancer inhibitors through molecular docking and molecular dynamics simulation. BioMed Research International, 2022, 3338549. https://doi.org/10.1155/2022/3338549
   PubMed Web of Science ®Google Scholar
• Pérez-Regidor, L., Zarioh, M., Ortega, L., & Martín-Santamaría, S. (2016). Virtual screening approaches towards the discovery of toll-like receptor modulators. International Journal of Molecular Sciences, 17(9), 1508. https://doi.org/10.3390/ijms17091508
   PubMed Web of Science ®Google Scholar
• Perry, J., Okamoto, M., Guiou, M., Shirai, K., Errett, A., & Chakravarti, A. (2012). Novel therapies in glioblastoma. Neurology Research International, 2012, 428565. https://doi.org/10.1155/2012/428565
   PubMedGoogle Scholar
• Purohit, R. (2014). Role of ELA region in auto-activation of mutant KIT receptor: A molecular dynamics simulation insight. Journal of Biomolecular Structure & Dynamics, 32(7), 1033–1046. https://doi.org/10.1080/07391102.2013.803264
   PubMed Web of Science ®Google Scholar
• Pusch, S., Krausert, S., Fischer, V., Balss, J., Ott, M., Schrimpf, D., Capper, D., Sahm, F., Eisel, J., Beck, A.-C., Jugold, M., Eichwald, V., Kaulfuss, S., Panknin, O., Rehwinkel, H., Zimmermann, K., Hillig, R. C., Guenther, J., Toschi, L., … von Deimling, A. (2017). Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 133(4), 629–644. https://doi.org/10.1007/s00401-017-1677-y
   PubMed Web of Science ®Google Scholar
• Ross, G. A., Morris, G. M., & Biggin, P. C. (2012). Rapid and accurate prediction and scoring of water molecules in protein binding sites. PLoS One. 7(3), e32036. https://doi.org/10.1371/journal.pone.0032036
   PubMed Web of Science ®Google Scholar
• Santhana Kumar, K., Brunner, C., Schuster, M., Kopp, L. L., Gries, A., Yan, S., Jurt, S., Moehle, K., Bruns, D., Grotzer, M., Zerbe, O., Schneider, G., & Baumgartner, M. (2023). Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth. Cellular Oncology (Dordrecht), 46(2), 331–356. https://doi.org/10.1007/s13402-022-00753-x
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2018–3. (2018). QikProp. Schrödinger.
   Google Scholar
• Sherman, W., Beard, H. S., & Farid, R. (2006). Use of an induced fit receptor structure in virtual screening. Chemical Biology & Drug Design, 67(1), 83–84. https://doi.org/10.1111/j.1747-0285.2005.00327.x
   PubMed Web of Science ®Google Scholar
• Singh, R., Bhardwaj, V., & Purohit, R. (2021). Identification of a novel binding mechanism of Quinoline based molecules with lactate dehydrogenase of Plasmodium falciparum. Journal of Biomolecular Structure & Dynamics, 39(1), 348–356. https://doi.org/10.1080/07391102.2020.1711809
   PubMed Web of Science ®Google Scholar
• Singh, S., Deora, H., Neyaz, A., Das, K. K., Mehrotra, A., Srivastava, A. K., Behari, S., Jaiswal, A. K., & Jaiswal, S. (2021). Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—Through the looking glass!. Egyptian Journal of Neurosurgery, 36(1), 107367. https://doi.org/10.1186/s41984-021-00118-w
   PubMedGoogle Scholar
• Singh, R., & Purohit, R. (2023). Computational analysis of protein-ligand interaction by targeting a cell cycle restrainer. Computer Methods and Programs in Biomedicine, 231, 107367. https://doi.org/10.1016/j.cmpb.2023.107367
   PubMed Web of Science ®Google Scholar
• Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., Kígyós, A., Tóvári, J., & Goldblum, A. (2022). Dual inhibitors of AChE and BACE-1 for reducing Aβ in Alzheimer’s disease: From in silico to in vivo. International Journal of Molecular Sciences, 23(21), 13098. https://doi.org/10.3390/ijms232113098
   PubMed Web of Science ®Google Scholar
• Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Sweta, J., Khandelwal, R., Srinitha, S., Pancholi, R., Adhikary, R., Ali, M. A., Nayarisseri, A., Vuree, S., & Singh, S. K. (2019). Identification of high-affinity small molecule targeting IDH2 for the clinical treatment of acute myeloid leukemia. Asian Pacific Journal of Cancer Prevention: APJCP, 20(8), 2287–2297. https://doi.org/10.31557/APJCP.2019.20.8.2287
   PubMedGoogle Scholar
• Szliszka, E., Czuba, Z. P., Domino, M., Mazur, B., Zydowicz, G., & Krol, W. (2009). In vitro evaluation of in silico screening approaches in search for selective ACE2 binding chemical probes. Molecules (Basel, Switzerland), 14(2), 738–754. https://doi.org/10.3390/molecules
   PubMedGoogle Scholar
• Veliz, I., Loo, Y., Castillo, O., Karachaliou, N., Nigro, O., & Rosell, R. (2015). Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Annals of Translational Medicine, 3(1), 1–14. https://doi.org/10.3978/j.issn.2305-5839.2014.10.06
   PubMedGoogle Scholar
• Wang, E., Sun, H., Wang, J., Wang, Z., Liu, H., Zhang, J. Z. H., & Hou, T. (2019). End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chemical Reviews, 119(16), 9478–9508. https://doi.org/10.1021/acs.chemrev.9b00055
   PubMed Web of Science ®Google Scholar
• Wang, P., Wu, J., Ma, S., Zhang, L., Yao, J., Hoadley, K. A., Wilkerson, M. D., Perou, C. M., Guan, K. L., Ye, D., & Xiong, Y. (2015). Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Cell Reports, 13(11), 2353–2361. https://doi.org/10.1016/j.celrep.2015.11.029
   PubMed Web of Science ®Google Scholar
• Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P. A., Kaminker, J. S., … Vogelstein, B. (2007). The genomic landscapes of human breast and colorectal cancers. Science (New York, N.Y.), 318(5853), 1108–1113. https://doi.org/10.1126/science.1145720
   PubMed Web of Science ®Google Scholar
• Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., Liu, L-x., Jiang, W-q., Liu, J., Zhang, J-y., Wang, B., Frye, S., Zhang, Y., Xu, Y-h., Lei, Q-y., … Xiong, Y. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell, 19(1), 17–30. https://doi.org/10.1016/j.ccr.2010.12.014
   PubMed Web of Science ®Google Scholar
• Yang, H., Ye, D., Guan, K. L., & Xiong, Y. (2012). IDH1 and IDH2 mutations in tumorigenesis: Mechanistic insights and clinical perspectives. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 18(20), 5562–5571. https://doi.org/10.1158/1078-0432.CCR-12-1773
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Sun, L., Li, H., Ai, L., Ma, Q., Qiao, X., Yang, J., Zhang, H., Ou, X., Wang, Y., Chen, G., Xue, J., Zhu, X., Zhao, Y., Yang, Y., & Liu, C. (2022). Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer. eLife, 11, 1–21. https://doi.org/10.7554/eLife.68481
   Web of Science ®Google Scholar